Potential interactions with anticancer agents: A cross-sectional study

Chemotherapy

Volumn 59, Issue 2, 2013, Pages 85-92

  Mouzon, A ^a   Kerger, J ^b   D'Hondt, L ^b   Spinewine, A ^b  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Antineoplastic agents; Drug interactions; Observational study; Oncology

Indexed keywords

ALCOHOL; AMIODARONE; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; COUMARIN; CYCLOPHOSPHAMIDE; DIURETIC AGENT; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; FENOFIBRATE; FLUOROURACIL; FUROSEMIDE; GEMCITABINE; HALOPERIDOL; HERBACEOUS AGENT; IRINOTECAN; METHOTREXATE; NAVELBINE; NON PRESCRIPTION DRUG; PRESCRIPTION DRUG; PROTON PUMP INHIBITOR; SALMETEROL; UNINDEXED DRUG; VALPROIC ACID; VITAMIN; ALPRAZOLAM; ENALAPRIL; FENTANYL; FOLIC ACID; HYDROCHLOROTHIAZIDE; LAPATINIB; PACLITAXEL; PANTOPRAZOLE; PEMETREXED; TRASTUZUMAB; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CROSS-SECTIONAL STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GRANULOCYTOPENIA; GRAPEFRUIT JUICE; HEART ARRHYTHMIA; HUMAN; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MYOPATHY; NEUROPATHY; OTOTOXICITY; PHARMACIST; PRIORITY JOURNAL; QT PROLONGATION; RAYNAUD PHENOMENON; SIDE EFFECT; SOLID TUMOR; TEACHING HOSPITAL; TOBACCO; TONIC CLONIC SEIZURE; TOXICITY; BELGIAN; CONTROLLED STUDY; DRUG INTERACTION; MALIGNANT NEOPLASTIC DISEASE; SHORT COURSE THERAPY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; CROSS-SECTIONAL STUDIES; DIURETICS; DRUG INTERACTIONS; FEMALE; HOSPITALS, TEACHING; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PROTON PUMP INHIBITORS;

EID: 84880292207     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000351133     Document Type: Article

References (43)

1. Hanigan MH, Dela Cruz BL, Thompson DM, Farmer KC, Medina PJ: Use of prescription and nonprescription medications and supplements by cancer patients during chemotherapy: questionnaire validation. J Oncol Pharm Pract 2008; 14: 123-130.
2. Green JL, Hawley JN, Rask KJ: Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharma-cother 2007; 5: 31-39. (Pubitemid 47099502)
3. Blower P, de Wit R, Goodin S, Aapro M: Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol 2005; 55: 117-142. (Pubitemid 40981915)
4. Buajordet I, Ebbesen J, Erikssen J, Brors O, Hilberg T: Fatal adverse drug events: the paradox of drug treatment. J Intern Med 2001; 250: 327-341. (Pubitemid 32955618)
5. Stockley IH: Stockley's Drug Interactions. Chicago, Pharmaceutical Press, 2008
6. ® 1.0 (Healthcare series), 2009
7. ® online. 2009. https://online. epocrates.com.
8. Beijnen JH, Schellens JH: Drug interactions in oncology. Lancet Oncol 2004; 5: 489-496. (Pubitemid 39069399)
9. Riechelmann RP, Saad ED: A systematic review on drug interactions in oncology. Cancer Invest 2006; 24: 704-712. (Pubitemid 44836174)
10. Riechelmann RP, Del Giglio A: Drug interactions in oncology: how common are they? Ann Oncol 2009; 20: 1907-1912.
11. Rédaction La Revue Prescrire: Eviter les effets indésirables par interactions médicamen-teuses: comprendre et décider. Rev Prescrire 2006; 26(suppl 278).
12. Ranchon F, Vantard N, Gouraud A, Schwiertz V, Franchon E, Pham BN, Vial T, You B, Bouafia F, Salles G, Rioufol C: Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report-should the practice be changed? Chemotherapy 2011; 57: 225-229.
13. Uno T, Yasui-Furukori N: Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006; 1: 157-161.
14. Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ: The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmaco-therapy 2004; 24: 1508-1514. (Pubitemid 39426346)
15. Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, Shear NH: Inducers of cytochrome p450 2e1 enhance methotrexate-induced hepatotoxicity. Clin Biochem 1999; 32: 519-536. (Pubitemid 30007763)
16. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK: Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592-600. (Pubitemid 47073540)
17. Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, Krzyza-nowska MK: Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 2008; 35: 535-543.
18. Jansman FG, Idzinga FS, Smit WM, de Graaf JC, Coenen JL, Sleijfer DT, Brouwers JR: Classification and occurrence of clinically significant drug interactions with irinotecan and ox-aliplatin in patients with metastatic colorectal cancer. Clin Ther 2005; 27: 327-335. (Pubitemid 40692751)
19. Riechelmann RP, Moreira F, Smaletz O, Saad ED: Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005; 56: 286-290. (Pubitemid 40941799)
20. Lemachatti J, Leveque D, Beretz L, Bergerat JP: Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients. Anticancer Res 2009; 29: 4741-4744.
21. van Leeuwen RW, Swart EL, Boom FA, Schuitenmaker MS, Hugtenburg JG: Potential drug interactions and duplicate prescriptions among ambulatory cancer patients: a prevalence study using an advanced screening method. BMC Cancer 2010; 10: 679.
22. Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, Mignot L: Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol 2011; 78: 220-226.
23. Vonbach P, Dubied A, Krahenbuhl S, Beer JH: Evaluation of frequently used drug interaction screening programs. Pharm World Sci 2008; 30: 367-374.
24. Wong CM, Ko Y, Chan A: Clinically significant drug-drug interactions between oral an-ticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother 2008; 42: 1737-1748.
25. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB: Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc 2004; 44: 136-141.
26. Vitry AI: Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol 2007; 63: 709-714. (Pubitemid 46753565)
27. Wang LM, Wong M, Lightwood JM, Cheng CM: Black box warning contraindicated co-medications: concordance among three major drug interaction screening programs. Ann Pharmacother 2010; 44: 28-34.
28. Barrons R: Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 2004; 61: 380-385. (Pubitemid 39004605)
29. Clauson KA, Polen HH, Marsh WA: Clinical decision support tools: performance of personal digital assistant versus online drug information databases. Pharmacotherapy 2007; 27: 1651-1658. (Pubitemid 350234314)
30. Clauson KA, Marsh WA, Polen HH, Seamon MJ, Ortiz BI: Clinical decision support tools: analysis of online drug information databases. BMC Med Inform Decis Mak 2007;7: 7.
31. Perkins NA, Murphy JE, Malone DC, Armstrong EP: Performance of drug-drug interaction software for personal digital assistants. Ann Pharmacother 2006;40:850-855. (Pubitemid 43765002)
32. Sparreboom A, Cox MC, Acharya MR, Figg WD: Herbal remedies in the united states: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-2503. (Pubitemid 41115408)
33. Werneke U, Earl J, Seydel C, Horn O, Crich-ton P, Fannon D: Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004;90:408-413. (Pubitemid 38250637)
34. McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK: Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 2004; 12: 454-462. (Pubitemid 38797102)
35. Yeung KS, Gubili J: Clinical guide to herb-drug interactions in oncology. J Soc Integr Oncol 2007;5:113-117. (Pubitemid 47555911)
36. Solimando DA: Drug Information Handbook for Oncology. Hudson, Lexi Comp, 2007.
37. About herbs, botanicals and other products. Integrative Medicine Service, Memorial Sloan-Kettering Cancer Center, New York. http://www.mskcc.org/ aboutherbs.
38. Williamson E, Driver S, Baxter K: Stockley's Herbal Medicines Interactions, ed 2. London, Pharmaceutical Press, 2013.
39. Mallet L, Spinewine A, Huang A: The challenge of managing drug interactions in elderly people. Lancet 2007;370:185-191. (Pubitemid 47042897)
40. Bink S, De Troy E: Interactions during oncological therapy: workshop on oncology. Leu-ven, ESCP Leuven, 2008.
41. Sokol KC, Knudsen JF, Li MM: Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther 2007; 32: 169-175. (Pubitemid 46449710)
42. Cancer patients at risk of drug interactions. CA Cancer J Clin 2007;57:258-259.
43. Riechelmann RP: Drug combinations with the potential to interact among cancer patients. Support Care Cancer 2007;15:1113-1114. (Pubitemid 47340976)